Immuno-oncology company Agenus Inc. (AGEN) announced Tuesday the FDA's clearance of AgenTus' IND application for an allogeneic iNKT therapy. AgenT-797 was submitted by AgenTus Therapeutics, a subsidiary of Agenus.
from RTT - Biotech https://ift.tt/2MjewSa
via IFTTT
No comments:
Post a Comment